Immune-mediated hemolytic anemia (IMHA) is an autoimmune condition where the body's immune system attacks and destroys its own red blood cells. This disease can seemingly manifest suddenly and severely and, as such, is an important cause of mortality in affected dogs. 

This program brings together the perspectives and expertise of specialists in both veterinary emergency and critical care and internal medicine to empower caretakers to make informed decisions regarding the care and management of dogs diagnosed with IMHA.

In this session (the second of a 2-part series) we continue the discussion regarding the management and treatment options for dogs with IMHA including:

• Options and indications for advanced therapies for dogs with IMHA and how these can impact patient outcomes
• Principals and practicality of therapeutic plasma exchange as a treatment for IMHA and how pet owners can access this treatment modality
• Long-term patient management
• The general prognosis for affected patients
• Medical benchmarks and drug side effects
  
  

Running time: 1 hr 28 mins (including 17 mins of question / answer)
Approved for 1.5 hrs of CE credit by AAVSB RACE and NY State